Doximity, Inc. (NYSE:DOCS) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of Doximity, Inc. (NYSE:DOCS) have been given a consensus recommendation of “Hold” by the twenty-five research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $30.59.

A number of brokerages recently issued reports on DOCS. JPMorgan Chase & Co. increased their target price on shares of Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Piper Sandler restated an “overweight” rating and issued a $47.00 price target (up from $42.00) on shares of Doximity in a research report on Friday, August 7th. Truist Financial upped their price objective on shares of Doximity from $19.00 to $24.00 and gave the stock a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings raised shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, October 6th. Finally, Stifel Nicolaus set a $27.00 price objective on shares of Doximity in a report on Tuesday, September 8th.

Recent Doximity Headlines

Investors following DOCS have been watching these headlines:

• Positive Sentiment: Doximity reportedly rolled out DoseCheck, a medication-dosing tool, following a period of near-zero drug-dosing errors. The product could support its offerings for healthcare professionals, though the article provides limited detail on its commercial impact. Doximity rolls out DoseCheck
• Neutral Sentiment: Barclays raised its DOCS price target to $30 from $27 while maintaining an “equal weight” rating. The higher target is a modest positive revision, but remains below the $33.28 share price cited in the provided background. Barclays sets a new price target
• Negative Sentiment: Several law firms publicized a securities class action covering investors who bought DOCS shares from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about engagement, competitive share and revenue expectations, including allegedly lowering and then missing fiscal 2026 guidance. The repeated announcements may renew concern about legal and reputational risk; the allegations remain unproven. Class action deadline and allegations

Doximity Price Performance

Doximity stock opened at $33.28 on Friday. The firm has a market capitalization of $5.93 billion, a P/E ratio of 46.22, a P/E/G ratio of 34.61 and a beta of 1.29. The stock has a fifty day moving average price of $29.61 and a two-hundred day moving average price of $25.36. Doximity has a 52-week low of $17.15 and a 52-week high of $51.85.

Doximity (NYSE:DOCS) last issued its earnings results on Thursday, November 5th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.19 by $0.17. Doximity had a net margin of 21.12% and a return on equity of 15.80%. The company had revenue of $174.54 million for the quarter. During the same quarter in the prior year, the firm posted $0.45 EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, equities research analysts predict that Doximity will post 0.74 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Timothy S. Cabral sold 10,721 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $35.00, for a total transaction of $375,235.00. Following the completion of the sale, the director directly owned 8,084 shares of the company’s stock, valued at $282,940. This trade represents a 57.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the sale, the chief accounting officer directly owned 101,432 shares of the company’s stock, valued at $3,111,933.76. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 22,701 shares of company stock valued at $717,401 over the last quarter. 31.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Doximity

Institutional investors and hedge funds have recently bought and sold shares of the business. Carmignac Gestion increased its stake in shares of Doximity by 127.8% in the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock valued at $100,480,000 after buying an additional 2,418,971 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Doximity during the 3rd quarter worth about $28,858,000. Swedbank AB lifted its position in Doximity by 1,147.9% during the 1st quarter. Swedbank AB now owns 1,010,559 shares of the company’s stock worth $23,546,000 after buying an additional 929,576 shares in the last quarter. First Trust Advisors LP lifted its position in Doximity by 1,527.1% during the 3rd quarter. First Trust Advisors LP now owns 793,646 shares of the company’s stock worth $22,492,000 after buying an additional 744,870 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Doximity by 29.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after acquiring an additional 694,300 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.